SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trading in a highly volatile spotlight following a public endorsement from President Trump, which has ignited intense debate between bulls citing the company's critical role in national security and bears echoing Michael Burry's skepticism regarding its valuation and competitive threats. The community remains sharply divided, with active discussion focused on whether the stock is primed for a major short squeeze driven by institutional accumulation or if it faces further downside as it navigates a challenging sector-wide software sell-off.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending as investors weigh conflicting indicators of institutional accumulation and ETF inflows against persistent geopolitical volatility and broader market uncertainty. Community sentiment remains deeply polarized, with active debates centered on whether current price levels represent a bottom-tier accumulation zone or a precursor to further macroeconomic instability.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is experiencing significant volatility driven by the U.S. government's announcement of a naval blockade in the Strait of Hormuz following the collapse of diplomatic talks with Iran. The community is sharply divided, with bulls betting on a quick market recovery despite geopolitical tensions, while bears point to the blockade as a major escalation that threatens global energy supply chains and complicates the broader macro outlook.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as investors rally behind a new multi-billion dollar strategic partnership with Nvidia that integrates their respective AI infrastructure and custom chip ecosystems. The community is actively discussing the stock's breakout potential as it reclaims key resistance levels, with many traders focusing on the company's surging optics business and long-term positioning within the AI supply chain.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is surging amid high-volume trading and speculative buzz surrounding its role as a decentralized entertainment protocol, with community members debating whether the rapid valuation jump is a sustainable momentum play or an overextended market trend. Discussion is heavily focused on the project's roadmap of global music events and perceived potential for future institutional partnerships, even as vocal skeptics warn of volatility risks and potential price manipulation.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging as investors closely monitor topline results from its Phase 2/3 OptimUM-02 trial evaluating darovasertib in metastatic uveal melanoma. The community is actively debating the potential for an accelerated approval filing and questioning the significance of the partnership with Servier ahead of this high-stakes data release.

WorldFinancial

WorldFinancial (WLFI) is currently polarizing the market, with bulls pointing to upcoming catalysts like the Mar-a-Lago crypto forum and potential institutional adoption, while skeptics view the token as a manipulated pump-and-dump scheme. The community is deeply divided between those betting on long-term utility and political alignment versus traders warning of significant dilution risks and historical volatility associated with the project.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as the community anticipates major near-term catalysts, including upcoming Phase 3 trial completions and pancreatic cancer data presentations at the Digestive Disease Week conference. Investor sentiment remains heavily bullish, driven by the companys strong cash position, recent analyst price target upgrades, and the high-conviction belief that its proprietary alpha-radiation technology is significantly undervalued.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and community members react to reports of a planned U.S. naval blockade in the Strait of Hormuz, fueling intense debate over global energy security and potential market volatility. Discussions are heavily polarized, with supporters praising the administration's aggressive geopolitical stance while critics express significant concern over the economic impact, diplomatic fallout, and the stability of the current presidential term.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors react to confirmed integration with key AI infrastructure, specifically its role in the photonic fabric utilized by Marvell and related data center partnerships. The community remains hyper-focused on the company's production scaling for its Optical Interposer platform, with active discussions weighing the high-risk, high-reward nature of its early-stage adoption against significant speculative interest in its potential role within future AI hardware ecosystems.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of InMed Pharmaceuticals surged to levels not seen in nearly five months, capturing significant attention from retail investors.&nbsp;The biopharma company, with a market cap of just under $4 million, announced on Tuesday that its INM-901 small molecule drug candidate for Alzheimer's disease demonstrated promising results in a recent clinical trial.The study showed that INM-901 significantly reduced several markers of neuroinflammation, both in plasma and the brain.&nbsp;Specifically, the high-dose treated group exhibited a dose-dependent reduction in pro-inflammatory cytokines and neurofilament light chain levels in the plasma.&nbsp;Additionally, the trial indicated a reduction in key neuroinflammatory genes in the brain, signaling a potential breakthrough in Alzheimer's treatment.Eric Hsu, InMed's Senior Vice President of Preclinical R&amp;D, expressed excitement over the results, noting, "The ability of INM-901 to actively reduce inflammation is an exciting development, as neuroinflammation has emerged as a promising new drug target beyond existing AD treatments focused primarily on removing amyloid beta plaques and tau protein tangles."&nbsp;He added, "INM-901 may address multiple pathological factors, making it a very promising drug candidate."The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform.&nbsp;One user expressed happiness with the stock's surge and speculated on the potential for a buy-out.<stembedurl>https://stocktwits.com/pennyman/message/600871159</stembedurl>Another suggested that InMed's current levels were too good an entry point to miss.<stembedurl>https://stocktwits.com/AmbushPredator/message/600878277</stembedurl>According to Koyfin data, InMed has only about 718,000 shares outstanding and a short interest of 1.3%.&nbsp;While <a href="https://stocktwits.com/symbol/INM">InMed's stock</a> is down nearly 30% over the past 12 months, it has gained approximately 14% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise

The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform. 

Equity

The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform. 


InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. It operates through the InMed Pharma and BayMedica Commercial segments. The InMed Pharma segment focuses on research and development. The BayMedica Commercial segment refers to manufacturing technologies to produce and commercialize bulk cannabinoids for sale as ingredients in the health and wellness industry. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

INM
InMed Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INM News

INMInMed Pharmaceuticals Inc